US venture Cytori Therapeutics Inc. has won limited approval in Japan for its Cytori Cell Therapy for restricted commercial clinical use in knee osteoarthritis, marking another feather in the cap of the country's efforts to expedite the availability of cell and regenerative therapies, and a new revenue stream for the loss-making San Diego-based company.
Limited Japan Nod For Cytori’s Osteoarthritis Cell Therapy
Japan's well-defined regulatory framework for cell and regenerative therapies has notched up another "win" with the limited-use approval of a product for knee osteoarthritis, which should also generate useful new revenues for originator Cytori.